Merck & Co., Inc.
MRKNYSEHealthcare● Active
$120.79
+$0.53(+0.44%)
Market Cap$298.3B
P/E Ratio—
52W High$125.14
52W Low$76.66
Merck & Co., Inc. (MRK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MRK · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$1.28
Est. -$1.47 · +12.9%
Revenue
$16.29B
Est. $15.85B · +2.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
MRK reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.00
Rev. $0.01B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.00
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Oct 29, 2026 | $2.29 | — | — | — | $17.38B | — |
| ◌ Q3 FY2026 | Aug 4, 2026 | $2.10 | — | — | — | $16.36B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | -$1.47 | -$1.28 | +12.9% | $16.29B | $15.85B | +2.8% |
| ▲ Q1 FY2026 | Feb 3, 2026 | $2.01 | $2.04 | +1.5% | $16.40B | $16.20B | +1.2% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $2.36 | $2.58 | +9.3% | $17.28B | $16.98B | +1.8% |
| ▲ Q3 FY2025 | Jul 29, 2025 | $2.03 | $2.13 | +4.9% | $15.81B | $15.86B | -0.4% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $2.13 | $2.22 | +4.2% | $15.53B | $15.34B | +1.2% |
| ▼ Q1 FY2025 | Feb 4, 2025 | $1.85 | $1.72 | -7.0% | $15.62B | $15.48B | +0.9% |
Q4 FY2026
Oct 29, 2026
EPS Actual
—
EPS Est.
$2.29
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$2.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
-$1.28
EPS Est.
-$1.47
EPS Surpr.
+12.9%
Revenue
$16.29B
Q1 FY2026
Feb 3, 2026Beat
EPS Actual
$2.04
EPS Est.
$2.01
EPS Surpr.
+1.5%
Revenue
$16.40B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$2.58
EPS Est.
$2.36
EPS Surpr.
+9.3%
Revenue
$17.28B
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
$2.13
EPS Est.
$2.03
EPS Surpr.
+4.9%
Revenue
$15.81B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$2.22
EPS Est.
$2.13
EPS Surpr.
+4.2%
Revenue
$15.53B
Q1 FY2025
Feb 4, 2025Miss
EPS Actual
$1.72
EPS Est.
$1.85
EPS Surpr.
-7.0%
Revenue
$15.62B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.45 | $2.50 | $2.58 | 2 |
| Q3 FY2027 | $2.62 | $2.67 | $2.75 | 1 |
| Q2 FY2027 | $2.23 | $2.27 | $2.34 | 1 |
| Q1 FY2027 | $2.09 | $2.13 | $2.20 | 2 |
| Q4 FY2026 | $1.96 | $2.00 | $2.06 | 2 |
| Q3 FY2026 | $2.25 | $2.29 | $2.33 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $18.4B | $18.7B | $19.1B | 3 |
| Q3 FY2027 | $18.7B | $18.9B | $19.4B | 2 |
| Q2 FY2027 | $17.1B | $17.4B | $17.8B | 2 |
| Q1 FY2027 | $16.4B | $16.7B | $17.1B | 3 |
| Q4 FY2026 | $16.5B | $16.7B | $17.1B | 3 |
| Q3 FY2026 | $17.1B | $17.4B | $17.8B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +12.9% | $110.95 | $109.18 | -1.60% |
| ▲ Q1 FY2026 | Feb 3, 2026 | +1.5% | $113.37 | $115.84 | +2.18% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +9.3% | $86.58 | $86.28 | -0.35% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +4.9% | $84.06 | $82.63 | -1.70% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +4.2% | $78.69 | $79.84 | +1.46% |
| ▼ Q1 FY2025 | Feb 4, 2025 | -7.0% | $99.79 | $90.74 | -9.07% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +4.7% | $104.83 | $102.32 | -2.39% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +6.0% | $127.78 | $115.25 | -9.81% |
Q2 FY2026-1.60%
Report Date
Apr 30, 2026
EPS Beat/Miss
+12.9%
Price Before
$110.95
Price After
$109.18
Q1 FY2026+2.18%
Report Date
Feb 3, 2026
EPS Beat/Miss
+1.5%
Price Before
$113.37
Price After
$115.84
Q4 FY2025-0.35%
Report Date
Oct 30, 2025
EPS Beat/Miss
+9.3%
Price Before
$86.58
Price After
$86.28
Q3 FY2025-1.70%
Report Date
Jul 29, 2025
EPS Beat/Miss
+4.9%
Price Before
$84.06
Price After
$82.63
Q2 FY2025+1.46%
Report Date
Apr 24, 2025
EPS Beat/Miss
+4.2%
Price Before
$78.69
Price After
$79.84
Q1 FY2025-9.07%
Report Date
Feb 4, 2025
EPS Beat/Miss
-7.0%
Price Before
$99.79
Price After
$90.74
Q4 FY2024-2.39%
Report Date
Oct 31, 2024
EPS Beat/Miss
+4.7%
Price Before
$104.83
Price After
$102.32
Q3 FY2024-9.81%
Report Date
Jul 30, 2024
EPS Beat/Miss
+6.0%
Price Before
$127.78
Price After
$115.25
Avg Beat Reaction-1.74%
Avg Miss Reaction-9.07%
Beat Rate7 / 8 quarters
Largest Move-9.81% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MRK ends December
Merck & Co., Inc. (MRK) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-1.28 — beating the analyst consensus of $-1.47 by +12.9%. MRK has beaten EPS estimates for 5 consecutive quarters. The next MRK earnings date is expected around September 1, 2026.
Each quarter, investors track MRK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MRK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MRK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MRK earnings · 5 questionsMerck & Co., Inc.'s next earnings report is expected around September 1, 2026. MRK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MRK historically reports after market close (AMC).
MRK earnings datewhen is MRK earningsMRK next earnings datewhen does MRK report earningsMRK earnings calendar
▸ Source: FMP · Merck & Co., Inc. SEC filings · US GAAP · Merck & Co., Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026